ArticleAlimentary pharmacology & therapeutics2026
Research Communication: Changing Aetiology of Chronic Liver Diseases in East Asia Pacific and HCC Surveillance in Non-Cirrhotic Patients.
Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
East Asia Pacific (EAP) faces a high burden of chronic liver disease (CLD), with metabolic dysfunction-associated steatotic liver disease (MASLD) projected to account for about 80% of CLD prevalence by 2040. Using Global Burden of Disease 2021 data, we assessed CLD trends, transitions to hepatocellular carcinoma (HCC), and the cost-effectiveness of non-cirrhotic HCC surveillance. Despite declining viral hepatitis burden, MASLD and alcohol-related CLD have risen. HCC surveillance in non-cirrhotic patients was cost-effective only for chronic hepatitis B in selected older age groups, with substantial variability across countries. These findings support refining surveillance guidelines and adaptation of risk stratification tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.